Improvements in the selective perception and training of rats using an original analog of the C-terminal fragment of vasopressin

Neuroscience and Behavioral Physiology

Volumn 30, Issue 2, 2000, Pages 225-229

  Ponomareva, N S ^a   Voskresenskaya, O G ^a   Kamenskii, A A ^a   Golubovich, V P ^b   Ashmarin, I P ^a  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Belarus)

Author keywords

Learning; Memory; Vasopressin fragment analog

Indexed keywords

ARGIPRESSIN DERIVATIVE; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; LEARNING; MEMORY; NONHUMAN; PERCEPTION; RAT; TRAINING;

EID: 0034088905     PISSN: 00970549     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02463162     Document Type: Article

References (12)

1. USSR Patent No. 1623166, 22 September 1990.
2. S. A. Titov, "The neurochemical bases of memory," in: Neurochemistry [in Russian], I. P. Ashmarin and P. I. Stukalov (Eds.), Institute of Biomedical Chemistry Press, Russian Academy of Medical Sciences, Moscow (1996), pp. 372-414.
3. V. P. Golubovich, P. V. Martinovich, A. B. Usenko, L. K. Slobodchikova, S. A. Titov, and I. P. Ashmarin, "Synthesis and biological activity of C-terminal fragments of vasopressin," Khim. Farm. Zh., 6, 675-679 (1988).
4. J. P. H. Burbach, G. L. Kovacs, D. de Wied, J. W. van Nispen, and H. M. Greven, "A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide," Science, 221, No. 4617, 1310-1312 (1983).
5. 7]AVP on learning and memory processes in rats with experimental amnesia," Pol. J. Pharmacol., 45, 11-22 (1993).
6. D. de Wied and W. H. Gispen, "Behavioral effects of peptides," in: Peptides in Neurobiology, H. Jainer (Ed.), Bethesda (1977), pp. 397-425.
7. D. de Wied, "Vasopressin and memory processes," in: Abstracts of 31st Int. Congress Physiol. Sci. Helsinki, 9-14 July 1989, p. 249.
8. S. N. Deyo, W. J. Shoemaker, A. Ettenberg, F. E. Bloom, and G. F. Koob, "Subcutaneous administration of behaviourally effective doses of arginine vasopressin change brain AVP content only in median eminence," Neuroendocrinology, 42, No. 3, 260-266 (1986).
9. J. J. Legros and M. Timsit-Berthier, "Vasopressin and vasopressin analogues for treatment of memory disorders in clinical practice," Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 12, 571-586 (1988).
10. C. Lin, Y. C. Du, and R. Y. Liu, "Cysteinyl methyl ester of AVP(4-8), a potent agonist, on the maintenance of passive avoidance in rats," Peptides, 11, No. 4, 633-639 (1990).
11. K. S. E. Su, K. M. Campanale, L. G. Mendelsohn, G. A. Kerchner, and C. L. Gries, "Nasal delivery of polypeptides. 1. Nasal absorption of enkephalins in rats," J. Pharm. Sci., 74, No. 4, 394-398 (1985).
12. R. Wan, D. de Wied, W. de Jong, and M. Diamant, "Differential effects of ACTH(4-10), DG-AVP and DG-OXT on heart and passive avoidance behavior in rats," Physiol. Behav., 51, No. 3, 507-513 (1992).